Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 23, 1997

View Archived Issues

Cell adhesion inhibitors claimed by Nippon Shinyaku

Toyama discloses antiplatelet agents

ACAT inhibitors from Takeda

SmithKline Beecham reports new antiinflammatory/antiallergic agents

New COX-2 inhibitor series disclosed by Merck Frosst

5-HT3/5-HT4 receptor ligands disclosed by Synthelabo

New antiasthma agents from Tanabe Seiyaku

NIH continues pivotal HIV-IG trial

Neurex compound headed for pivotal trials in head trauma

Glaxo Wellcome claims new formulation of anxiolytic agent

Almirall and Prodesfarma heading for merger

Panax and Sangen to combine

Raloxifene for inhibition of vascular smooth muscle cell migration

Smoking definitively linked to cardiovascular morbidity and mortality

MAb from Hayashibara with IFN-inducing properties

Clinical results of gabapentin in ALS reported

Inhibitors of alpha-amylase disclosed by Japanese researchers

Eisai discloses IL-1 inhibitors

Connective Therapeutics advances development of interferon

BMS cognition enhancer not superior to placebo in clinical study

New AMPA receptor modulator described by Servier

TBC receives patent coverage for endothelin antagonists

New tool for studying phosphodiesterase receptors

FDA expands orphan drug designation for NTZ

Labopharm and Sepracor to develop solid oral form of levalbuterol

ID Biomedical developing TB test

NIH offers licenses for conjugate vaccine

NIH seeks licensees for dopamine reuptake inhibitors

NIH offers licenses for IDDM markers

NIH seeks licensees for perilipins

Collaborators sought for gene therapy technology

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...